Loading…
QUETIAPINE HEC PHARM is a brand name for Quetiapine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Quetiapine HEC Pharm is indicated for: treatment of schizophrenia. treatment of bipolar disorder: For the treatment of moderate to severe manic episodes in bipolar disorder For the treatment of major depressive episodes in bipolar disorder For the prevention of recurrence of manic or depressed episodes in…
Verbatim from this product's MHRA label. Tap a section to expand.
Different dosing schedules exist for each indication. It must therefore be ensured that patients receive clear information on the appropriate dosage for their condition. Adults For the treatment of schizophrenia For the treatment of schizophrenia, Quetiapine HEC Pharm should be administered twice a day.
The total daily dose for the first four days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4). From Day 4 onwards, the dose should be titrated to the usual effective dose of 300 to 450 mg/day. Depending on the clinical response and tolerability of the individual patient, the dose may be adjusted within the range 150 to 750 mg/day.
For the treatment of moderate to severe manic episodes in bipolar disorder For the treatment of manic episodes associated with bipolar disorder, Quetiapine HEC Pharm should be administered twice a day. The total daily dose for the first four days of therapy is 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4).
Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no greater than 200 mg/day. The dose may be adjusted depending on clinical response and tolerability of the individual patient, within the range of 200 to 800 mg/day.
The usual effective dose is in the range of 400 to 800 mg/day. For the treatment of major depressive episodes in bipolar disorder Quetiapine HEC Pharm should be administered once daily at bedtime. The total daily dose for the first four days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4).
The recommended daily dose is 300 mg. 1). Individual patients may benefit from a 600 mg dose. Doses greater than 300 mg should be initiated by physicians experienced in treating bipolar disorder. In individual patients, in the event of tolerance concerns, clinical trials have indicated that dose reduction to a minimum of 200 mg could be considered.
For preventing recurrence in bipolar disorder For preventing recurrence of manic, mixed or depressive episodes in bipolar disorder, patients who have responded to quetiapine for acute treatment of bipolar disorder should continue therapy at the same dose.
The dose may be adjusted depending on clinical response and tolerability of the individual patient, within the range of 300 to 800 mg/day administered twice daily. It is important that the lowest effective dose is used for maintenance therapy.
The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine (≥10%) are somnolence, dizziness, headache, dry mouth, withdrawal (discontinuation) symptoms, elevations in serum triglyceride levels, elevations in total cholesterol (predominantly LDL cholesterol), decreases in HDL cholesterol, weight gain, decreased haemoglobin and extrapyramidal symptoms.
The incidences of ADRs associated with quetiapine therapy, are tabulated below (Table 1) according to the format recommended by the Council for International Organizations of Medical Sciences (CIOMS III Working Group; 1995). Table 1 ADRs associated with quetiapine therapy The frequencies of adverse events are ranked according to the following: Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
SOC Very Common Common Uncommon Rare Very Rare Not known Blood and lymphatic system disorders Decreased haemoglobin22 Leucopenia1, 28, decreased neutrophil count, eosinophils increased27 Neutropenia1, Thrombocytopeni a, Anaemia, platelet count decreased13 Agranulocytosis 26 Immune system disorders Hypersensitivity (including allergic skin reactions) Anaphylactic reaction5 Endocrine disorders Hyperprolactinaemi a 15, decreases in total T4 24, decreases in free T4 24, decreases in total T3 24, increases in TSH24 Decreases in free T3 24, Hypothyroidism21 Inappropriate antidiuretic hormone secretion Metabolism and nutritional disorders Elevations in serum triglyceride levels10,30 Elevations in total cholesterol (predominantly LDL cholesterol)11,30 Decreases in HDL cholesterol17,30, Weight gain8,30 Increased appetite, blood glucose increased to hyperglycaemic levels6, 30 Hyponatraemia19, Diabetes Mellitus 1,5 Exacerbation of pre-existing diabetes Metabolic syndrome29 Psychiatric disorders Abnormal dreams and nightmares, Suicidal ideation and suicidal behaviour20 Somnambulism and related reactions such as sleep talking and sleep related eating disorder Nervous system disorders Dizziness4, 16, somnolence2,16, headache, Extrapyramidal symptoms1, 21 Dysarthria Seizure1, Restless legs syndrome, Tardive dyskinesia1, 5, Syncope4,16 Eye disorders Vision blurred Cardiac disorders Tachycardia4, Palpitations23 QT prolongation1,12, 18 Bradycardia32 Vascular disorders Orthostatic hypotension4,16 Venous thromboembolis m1 Stroke33 SOC Very Common Common Uncommon Rare Very Rare Not known Respiratory, thoracic and mediastinal disorder Dyspnoea23 Rhinitis Gastrointestinal disorders Dry mouth Constipation, dyspepsia, vomiting25 Dysphagia7 Pancreatitis1, Intestinal obstruction/ Ileus Hepato-biliary disorders Elevations in serum alanine aminotransferase (ALT)3, Elevations in gamma-GT levels3 Elevations in serum aspartate aminotransferase (AST)3 Jaundice5, Hepatitis Skin and subcutaneous tissue disorders Angioedema5, Stevens-Johnson syndrome5 Toxic Epidermal Necrolysis, Erythema Multiforme Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary retention Pregnancy, puerperium and perinatal conditions Drug withdrawal syndrome neonatal31 Reproductive system and breast disorders Sexual dysfunction Priapism, galactorrhoea, breast swelling, menstrual disorder General disorders and administration site conditions Withdrawal (discontinuation ) symptoms1,9 Mild asthenia, peripheral oedema, irritability, pyrexia Neuroleptic malignant syndrome1, hypothermia Investigations Elevations in blood creatine phosphokinase14 1.
As Quetiapine HEC Pharm has several indications, the safety profile should be considered with respect to the individual patient’s diagnosis and the dose being administered. Suicide/suicidal thoughts or clinical worsening Depression in bipolar disorder is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events).
This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
In addition, physicians should consider the potential risk of suicide-related events after abrupt cessation of quetiapine treatment, due to the known risk factors for the disease being treated. Other psychiatric conditions for which quetiapine is prescribed can also be associated with an increased risk of suicide related events.
In addition, these conditions may be co-morbid with major depressive episodes. The same precautions observed when treating patients with major depressive episodes should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.
A meta analysis of placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany therapy with medicinal products especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
1. 5).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Quetiapine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Quetiapine HEC Pharm can be administered with or without food. Special populations Elderly Quetiapine HEC Pharm should be used with caution in the elderly, especially during the initial dosing period. The rate of dose titration may need to be slower, and the daily therapeutic dose lower, than that used in younger patients, depending on the clinical response and tolerability of the individual patient.
The mean plasma clearance of quetiapine was reduced by 30-50% in elderly subjects when compared to younger patients. Efficacy and safety has not been evaluated in patients over 65 years with depressive episodes in the framework of bipolar disorder.
Renal impairment Dose adjustment is not necessary in patients with renal impairment. Hepatic impairment Quetiapine is extensively metabolised by the liver. Therefore, Quetiapine HEC Pharm should be used with caution in patients with known hepatic impairment, especially during the initial dosing period.
Patients with known hepatic impairment should be started with 25 mg/day. The dose should be increased daily with increments of 25-50 mg/day until an effective dose, depending on the clinical response and tolerability of the individual patient.
Paediatric population Quetiapine HEC Pharm is not recommended for use in children and adolescents below 18 years of age, due to a lack of data to support use in this age group. 2. Method of administration Quetiapine HEC Pharm is for oral use.
4. 2. Somnolence may occur, usually during the first two weeks of treatment and generally resolves with the continued administration of quetiapine. 3. Asymptomatic elevations (shift from normal to > 3X ULN at any time) in serum transaminase (ALT, AST) or gamma-GT-levels have been observed in some patients administered quetiapine.
These elevations were usually reversible on continued quetiapine treatment. 4. 4).
0% vs. 0%, respectively). A population-based retrospective study of quetiapine for the treatment of patients with major depressive disorder showed an increased risk of self-harm and suicide in patients aged 25 to 64 years without a history of self-harm during use of quetiapine with other antidepressants.
Metabolic risk Given the observed risk for worsening of their metabolic profile, including changes in weight, blood glucose (see hyperglycemia) and lipids, which was seen in clinical studies, patients’ metabolic parameters should be assessed at the time of treatment initiation and changes in these parameters should be regularly controlled for during the course of treatment.
8). 1). The use of quetiapine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment.
In patients who develop these symptoms, increasing the dose may be detrimental. Tardive dyskinesia If signs and symptoms of tardive dyskinesia appear, dose reduction or discontinuation of quetiapine should be considered. 8). 8). In clinical trials for treatment of patients with bipolar depression, onset was usually within the first 3 days of treatment and was predominantly of mild to moderate intensity.
Patients experiencing somnolence of severe intensity may require more frequent contact for a minimum of 2 weeks from onset of somnolence, or until symptoms improve and treatment discontinuation may need to be considered. 8) which, like somnolence has onset usually during the initial dose-titration period.
This could increase the occurrence of accidental injury (fall), especially in the elderly population. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.
Quetiapine should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension. Dose reduction or more gradual titration should be considered if orthostatic hypotension occurs, especially in patients with underlying cardiovascular disease.
Sleep apnoea syndrome Sleep apnoea syndrome has been reported in patients using quetiapine. In patients receiving concomitant central nervous system depressants and who have a history of or are at risk for sleep apnoea, such as those who are overweight/obese or are male, quetiapine should be used with caution.
Seizures In controlled clinical trials there was no difference in the incidence of seizures in patients treated with quetiapine or placebo. No data is available about the incidence of seizures […]